Drugs / MK2461
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00518739 | Feb 2007 → Dec 2008 | cancer of unknown primary site | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00496353 | Jun 2007 → Oct 2008 | neoplasm | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK2461 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00496353 ↗ |
| Action | Inhibit | “Hepatocyte growth factor receptor inhibitor” CHEMBL1822792 ↗ |
| Modality | Small molecule | — CHEMBL1822792 ↗ |
| Route | Oral | “Patients will be administered oral MK2461 twice daily” NCT00518739 ↗ |
| Target | MET | “Hepatocyte growth factor receptor inhibitor” CHEMBL1822792 ↗ |